{"title":"A study to learn if nirogacestat works and is safe for adult participants with desmoid tumors: a plain language summary of the DeFi study.","authors":"Bernd Kasper, Jeanne Whiting, Dana Lawson, Marlene Portnoy, Kathrin Schuster, Christina Baumgarten, Ravin Ratan, Allison Lim, Sunny Cho, Shivaani Kummar, Mrinal Gounder","doi":"10.1080/14796694.2025.2462519","DOIUrl":"https://doi.org/10.1080/14796694.2025.2462519","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-13"},"PeriodicalIF":3.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-03-07DOI: 10.1080/14796694.2025.2470108
Neal D Shore, Daniel J George, Daniel E Spratt, Jose De La Cerda
{"title":"The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer.","authors":"Neal D Shore, Daniel J George, Daniel E Spratt, Jose De La Cerda","doi":"10.1080/14796694.2025.2470108","DOIUrl":"https://doi.org/10.1080/14796694.2025.2470108","url":null,"abstract":"<p><p>Relugolix is a once-daily oral gonadotropin-releasing hormone antagonist that was approved by the U.S. Food and Drug Administration in 2020 for the treatment of advanced prostate cancer. Relugolix is commonly co-prescribed with complementary oncologic therapies or agents targeting associated comorbidities (e.g. cardiovascular disease). In this podcast, we review studies which evaluate relugolix with concomitant next-generation hormonal therapies (abiraterone, apalutamide, and enzalutamide), chemotherapy (docetaxel), radiotherapy, and common cardiovascular medications (antihypertensives, antithrombotics, and lipid‑lowering agents). Based on these studies, these therapies do not appear to affect relugolix efficacy and no new safety concerns were reported.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-5"},"PeriodicalIF":3.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-03-06DOI: 10.1080/14796694.2025.2468578
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Aref Al-Kali, H Joachim Deeg, Mitchell Sabloff, Mary-Margaret Keating, Nancy Zhu, Nashat Y Gabrail, Salman Fazal, Joseph Maly, Olatoyosi Odenike, Amy E DeZern, Casey L O'Connell, Gail J Roboz, Lambert Busque, Rena Buckstein, Harshad Amin, Brian Leber, Aditi Shastri, Aram Oganesian, Harold N Keer, Mohammad Azab, Michael R Savona
{"title":"A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.","authors":"Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Aref Al-Kali, H Joachim Deeg, Mitchell Sabloff, Mary-Margaret Keating, Nancy Zhu, Nashat Y Gabrail, Salman Fazal, Joseph Maly, Olatoyosi Odenike, Amy E DeZern, Casey L O'Connell, Gail J Roboz, Lambert Busque, Rena Buckstein, Harshad Amin, Brian Leber, Aditi Shastri, Aram Oganesian, Harold N Keer, Mohammad Azab, Michael R Savona","doi":"10.1080/14796694.2025.2468578","DOIUrl":"https://doi.org/10.1080/14796694.2025.2468578","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-13"},"PeriodicalIF":3.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-03-06DOI: 10.1080/14796694.2025.2463318
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, Ying Cheng, Chee Khoon Lee, Natalia Valdiviezo, Konstantin Laktionov, Tsung-Ying Yang, Yan Yu, Terufumi Kato, Liyan Jiang, Busyamas Chewaskulyong, Sarayut Lucien Geater, Jean-Marc Maurel, Carlos Rojas, Toshiaki Takahashi, Frances A Shepherd, Kentaro Tanaka, Dana Ghiorghiu, Neha P Amin, Elena Armenteros-Monterroso, Xiangning Huang, Ammar Ahmed Chaudhry, James Chih-Hsin Yang
{"title":"A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.","authors":"Pasi A Jänne, David Planchard, Kunihiko Kobayashi, Ying Cheng, Chee Khoon Lee, Natalia Valdiviezo, Konstantin Laktionov, Tsung-Ying Yang, Yan Yu, Terufumi Kato, Liyan Jiang, Busyamas Chewaskulyong, Sarayut Lucien Geater, Jean-Marc Maurel, Carlos Rojas, Toshiaki Takahashi, Frances A Shepherd, Kentaro Tanaka, Dana Ghiorghiu, Neha P Amin, Elena Armenteros-Monterroso, Xiangning Huang, Ammar Ahmed Chaudhry, James Chih-Hsin Yang","doi":"10.1080/14796694.2025.2463318","DOIUrl":"https://doi.org/10.1080/14796694.2025.2463318","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-03-05DOI: 10.1080/14796694.2025.2471200
Elena Castro, Di Wang, Sarah Walsh, Samantha Craigie, Anja Haltner, Jonathan Nazari, Alexander Niyazov, Imtiaz A Samjoo
{"title":"Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC.","authors":"Elena Castro, Di Wang, Sarah Walsh, Samantha Craigie, Anja Haltner, Jonathan Nazari, Alexander Niyazov, Imtiaz A Samjoo","doi":"10.1080/14796694.2025.2471200","DOIUrl":"10.1080/14796694.2025.2471200","url":null,"abstract":"<p><strong>Aims: </strong>The absence of direct comparisons between talazoparib plus enzalutamide (TALA+ENZA) and current standard of care hinders evaluating their relative efficacy for first-line (1 L) metastatic castration resistant prostate cancer (mCRPC). This study aimed to compare TALA+ENZA (TALAPRO-2) to abiraterone acetate plus prednisone (AAP) (COU-AA-302) and docetaxel (TAX 327) using a matching-adjusted indirect treatment comparison (MAIC).</p><p><strong>Methods: </strong>A systematic literature review using the Ovid® interface was performed to identify relevant evidence. Patient-level data from TALAPRO-2 and published data from COU-AA-302 and TAX 327 were used to match populations on clinically relevant confounders. The MAICs were conducted for radiographic progression-free survival (rPFS), overall survival (OS), objective response rate (ORR), along with additional efficacy outcomes.</p><p><strong>Results: </strong>In all-comers, TALA+ENZA statistically significantly prolonged rPFS (HR: 0.256; 95% confidence interval [CI]: 0.183, 0.359; <i>p</i> < 0.0001), OS (HR: 0.557; 0.405, 0.766; <i>p</i> = 0.0003), and improved ORR (OR: 3.924; 2.017, 7.634; <i>p</i> = 0001) versus AAP. In all-comers, TALA+ENZA significantly prolonged OS (HR: 0.446; 0.316, 0.631; <i>p</i> < 0.0001) and improved ORR (OR: 13.081; 5.757, 29.721; <i>p</i> < 0.0001) versus docetaxel. All other efficacy outcomes statistically favored TALA+ENZA.</p><p><strong>Conclusions: </strong>These results suggest TALA+ENZA improves clinical outcomes relative to AAP and docetaxel in the 1 L mCRPC all-comers population.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-03-03DOI: 10.1080/14796694.2025.2468569
Ángel Borque-Fernando, Teresa Alonso-Gordoa, María José Juan-Fita, Fernando Lopez Campos, Daniel Adolfo Pérez-Fentes, Antoni Vilaseca, Cristina Moretones Agut, Paola Usán, Pablo Maroto Rey
{"title":"Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.","authors":"Ángel Borque-Fernando, Teresa Alonso-Gordoa, María José Juan-Fita, Fernando Lopez Campos, Daniel Adolfo Pérez-Fentes, Antoni Vilaseca, Cristina Moretones Agut, Paola Usán, Pablo Maroto Rey","doi":"10.1080/14796694.2025.2468569","DOIUrl":"10.1080/14796694.2025.2468569","url":null,"abstract":"<p><p>This review explores the complexities of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), emphasizing the limitations of using disease volume and metastatic timing as sole prognostic factors. Current algorithms focus on clinical factors like ECOG, comorbidities, and patient preferences, yet lack biomarkers for more individualized therapy. By examining prognostic indicators - clinical, analytical, pathological, molecular, and imaging - this article highlights the importance of a personalized approach. Multimodal strategies and predictive biomarkers are proposed to optimize therapy selection between doublet and triplet regimens, ultimately improving patient outcomes. Future trials incorporating emerging biomarkers may provide the basis for precision treatment in mHSPC, shifting management beyond conventional classifications.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-13"},"PeriodicalIF":3.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-03-03DOI: 10.1080/14796694.2025.2470609
Marlies Michl, Nora Hagemeyer, Marion Looß, Sina Grebhardt, Kai Ringwald, Karin Potthoff
{"title":"IDHIRA: a prospective, observational study on ivosidenib in patients with <i>IDH1</i> R132-mutated advanced cholangiocarcinoma.","authors":"Marlies Michl, Nora Hagemeyer, Marion Looß, Sina Grebhardt, Kai Ringwald, Karin Potthoff","doi":"10.1080/14796694.2025.2470609","DOIUrl":"10.1080/14796694.2025.2470609","url":null,"abstract":"<p><strong>Clinical trial registration: </strong>www.clinicaltrials.gov identifier is NCT06607302.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-03-01Epub Date: 2025-01-17DOI: 10.1080/14796694.2024.2440277
Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, Andrew J Martin, Wendy Parulekar, Eibhlin Mulroe, Margaret McJannett, Robert R Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen K Sandhu, M Neil Reaume, David W Pook, Scott A North, Gavin M Marx, Anthony Joshua, Lisa Horvath, Ray McDermott, Simon Chowdhury, Kim N Chi, Alison Y Zhang, Martin R Stockler, Ian D Davis, Christopher J Sweeney
{"title":"Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).","authors":"Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, Andrew J Martin, Wendy Parulekar, Eibhlin Mulroe, Margaret McJannett, Robert R Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen K Sandhu, M Neil Reaume, David W Pook, Scott A North, Gavin M Marx, Anthony Joshua, Lisa Horvath, Ray McDermott, Simon Chowdhury, Kim N Chi, Alison Y Zhang, Martin R Stockler, Ian D Davis, Christopher J Sweeney","doi":"10.1080/14796694.2024.2440277","DOIUrl":"10.1080/14796694.2024.2440277","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"627-636"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-03-01Epub Date: 2024-12-18DOI: 10.1080/14796694.2024.2440255
Claire Harrison, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Ruben A Mesa
{"title":"Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary.","authors":"Claire Harrison, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Ruben A Mesa","doi":"10.1080/14796694.2024.2440255","DOIUrl":"10.1080/14796694.2024.2440255","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"617-625"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-03-01Epub Date: 2025-02-12DOI: 10.1080/14796694.2025.2458458
Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana, Christelle De La Fouchardière, Andrew Dean, Igor Kiss, Woo Jin Leei, Thorsten O Goetze, Eric Van Cutsem, A Scott Paulson, Tanios Bekaii-Saab, Shubham Pant, Richard A Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, Eileen M O'Reilly
{"title":"A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).","authors":"Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana, Christelle De La Fouchardière, Andrew Dean, Igor Kiss, Woo Jin Leei, Thorsten O Goetze, Eric Van Cutsem, A Scott Paulson, Tanios Bekaii-Saab, Shubham Pant, Richard A Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, Eileen M O'Reilly","doi":"10.1080/14796694.2025.2458458","DOIUrl":"10.1080/14796694.2025.2458458","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"765-774"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
